Recor Medical v. Medtronic Ireland — Federal Circuit Applies ALM Standing Rule to Medical Device Patent Dispute

Background

Medtronic Ireland owns two patents covering renal neuromodulation systems—technology that uses thermal energy to treat hypertension by modulating neural fibers related to kidney function. Medtronic Ireland licensed exclusive rights to manufacture and sell products under these patents to its affiliate, Medtronic Galway, through an Exclusive License Agreement (ELA). Under the ELA, Medtronic Ireland retained a secondary right to sue for infringement (if Medtronic Galway declined), veto authority over sublicenses, royalty interests, and control over which “Products” fell within the license’s scope.

Recor Medical, maker of a competing renal denervation system called the Paradise System, sued Medtronic Ireland for a declaration of noninfringement and invalidity. When Medtronic Ireland asserted patent infringement counterclaims, Recor moved to dismiss, arguing that the ELA had stripped Medtronic Ireland of the exclusionary rights needed for constitutional standing. The Northern District of California agreed, relying on Morrow v. Microsoft Corp., and dismissed the counterclaims.

The Court’s Holding

The Federal Circuit reversed, applying its same-day precedential decision in A.L.M. Holding Co. v. Zydex Industries (No. 25-1317). Judge Chen, writing for a unanimous panel, held that Medtronic Ireland’s retained rights—the right to sue, sublicensing veto, and royalty interests—were “materially the same” as those that conferred standing in ALM.

The court first rejected Recor’s mootness argument. After the district court’s dismissal, Medtronic had amended the ELA and filed a new lawsuit (Recor II) seeking the same relief. But the Federal Circuit found that legal consequences still flowed from the original dismissal—specifically, Recor’s unclean-hands defense in Recor II depended on the premise that Medtronic Ireland lacked standing in the original suit. A reversal would undercut that defense.

On the merits, the court emphasized that even a secondary right to sue (one that activates only if the primary licensee declines) is not insubstantial—once triggered, the patent owner has “complete control and discretion over the litigation.” The court also noted that Medtronic Ireland retained control over which products fell within the license, because “Product” required its specific designation. For un-designated products, Medtronic Ireland retained all exclusionary rights.

The case was remanded for the district court to address joinder of Medtronic Galway as a necessary party for statutory standing purposes.

Key Takeaways

• Secondary rights to sue preserve standing. A patent owner whose right to sue activates only when its licensee declines still has a meaningful, non-illusory enforcement right.
• Intra-corporate licensing does not destroy standing. Even where the patent owner and licensee are affiliates within the same corporate family, Article III standing turns on the formal rights retained, not the parties’ relationship.
• Product designation clauses add exclusionary power. A license limited to “specifically designated” products preserves the patent owner’s exclusionary rights over all un-designated uses of the patented technology.
• Refiling does not moot the original appeal. When legal consequences of the original dismissal persist in related litigation, the appeal remains live.

Why It Matters

This nonprecedential companion to ALM Holding v. Zydex demonstrates how the Federal Circuit’s new standing framework applies in practice—specifically in the common scenario where a multinational corporation assigns patent rights to one entity and manufacturing/sales rights to another. The decision reassures companies with complex intra-group licensing that structured patent holding arrangements do not automatically forfeit standing. It also signals that district courts should look beyond the label “exclusive license” to examine what rights the patent owner actually retained before dismissing for lack of standing.